Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2012. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific personnel transactions rather than a financial performance report.
Material Changes
No material changes to financial performance or business operations are reported. The filing details a revaluation of the cash element of a notional investment held within the US Retirement Savings Plan, resulting in an increase in the notional allocation of American Depositary Shares (ADSs) on August 3, 2012, at a price of $46.68 per ADS.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly addresses compliance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Important Facts for Investors
- Transaction Date: The notional allocation increase occurred on August 3, 2012.
- Price: The transaction price was $46.68 per ADS.
- Parties Involved: The transaction involved Dr. M M Slaoui (Director) and Dr. K Slaoui (Connected Person).
- Allocation Details: Dr. M M Slaoui received no additional ADSs, while Dr. K Slaoui received 4 ADSs.
- Document Type: This is a notification of director/connected person transactions, not a financial earnings release.